Dongying Zhou

Dongying Zhou has held several roles in the field of research and drug discovery. From 2022 to 2023, Zhou worked as a Drug Discovery CO-OP at Pfizer, where they studied the effect of target receptor knockout on various genes and explored the ligand and downstream signaling pathway of the target. In 2023, Zhou joined ReNAgade Therapeutics as a Senior Research Associate.

Dongying Zhou attended the University of California, Davis from 2016 to 2019, where they earned a Bachelor of Science degree in Biochemistry and Molecular Biology. Following this, Zhou enrolled at Brown University in 2020 and is expected to complete a Master of Science degree in Biotechnology in 2022.